AQR Capital Management
RCUS icon

AQR Capital Management’s Arcus Biosciences RCUS Stock Holding History

AQR Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.59M Sell
83,861
-2,433
-3% -$60.1K ﹤0.01% 2452
2026
Q1 		$1.86M Buy
86,294
+87
+0.1% +$1.88K ﹤0.01% 2398
2025
Q4 		$2.05M Buy
86,207
+2,430
+3% +$49.6K ﹤0.01% 2116
2025
Q3 		$1.14M Sell
83,777
-24,522
-23% -$255K ﹤0.01% 2351
2025
Q2 		$882K Buy
108,299
+17,345
+19% +$148K ﹤0.01% 2286
2025
Q1 		$714K Buy
90,954
+65,254
+254% +$757K ﹤0.01% 2227
2024
Q4 		$383K Sell
25,700
-390
-1% -$6.37K ﹤0.01% 2381
2024
Q3 		$399K Buy
26,090
+1,566
+6% +$24.7K ﹤0.01% 2268
2024
Q2 		$374K Buy
24,524
+9,916
+68% +$160K ﹤0.01% 2183
2024
Q1 		$276K Buy
14,608
+3,661
+33% +$63.3K ﹤0.01% 2157
2023
Q4 		$209K Buy
+10,947
New +$175K ﹤0.01% 2199
2023
Q2 		– Sell
-221,257
Closed -$4.04M – 2264
2023
Q1 		$4.04M Buy
221,257
+100,293
+83% +$1.92M 0.01% 988
2022
Q4 		$2.5M Buy
120,964
+856
+0.7% +$23.6K 0.01% 1165
2022
Q3 		$3.14M Buy
120,108
+49,775
+71% +$1.32M 0.01% 1007
2022
Q2 		$1.78M Buy
+70,333
New +$1.72M ﹤0.01% 1149
2021
Q4 		– Sell
-5,869
Closed -$205K – 2265
2021
Q3 		$205K Sell
5,869
-31,770
-84% -$989K ﹤0.01% 2148
2021
Q2 		$1.03M Sell
37,639
-9,587
-20% -$274K ﹤0.01% 1579
2021
Q1 		$1.33M Sell
47,226
-18,740
-28% -$652K ﹤0.01% 1427
2020
Q4 		$1.71M Buy
65,966
+526
+0.8% +$12.7K ﹤0.01% 1242
2020
Q3 		$1.12M Buy
65,440
+7,278
+13% +$163K ﹤0.01% 1364
2020
Q2 		$1.44M Buy
58,162
+32,186
+124% +$869K ﹤0.01% 1308
2020
Q1 		$361K Sell
25,976
-971
-4% -$12.1K ﹤0.01% 1696
2019
Q4 		$272K Buy
+26,947
New +$227K ﹤0.01% 1932

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

AQR Capital Management's RCUS Position: Q2 2026 in Review

AQR Capital Management reduced its Arcus Biosciences (RCUS) stake by 2.8% in Q2 2026, selling an estimated $60.1K and leaving 83,861 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #2452.

AQR Capital Management first reported a position in RCUS in Q4 2019 and has held it in 23 quarters since. The position peaked at $4.04M in Q1 2023. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • AQR Capital Management held 83,861 shares of Arcus Biosciences worth $2.59M as of Q2 2026.
  • AQR Capital Management sold 2,433 Arcus Biosciences shares in Q2 2026, an estimated $60.1K.
  • Arcus Biosciences made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2452 holding.
  • AQR Capital Management first reported a position in Arcus Biosciences in Q4 2019 and has held it in 23 quarters since.
  • AQR Capital Management's Arcus Biosciences position peaked at $4.04M in Q1 2023.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.